Efficacy and Safety of Midodrine and Atomoxetine for Neurogenic OH
Status:
Completed
Trial end date:
2019-03-15
Target enrollment:
Participant gender:
Summary
This was a randomized, open-label clinical trial. We will enroll patients with symptomatic
neurogenic OH and randomize them to 1 of 2 treatments: (1) midodrine only, (2) atomoxetine
only. We will follow up patients at 1 and 3 months after treatment. If the patients meet BP
criteria for OH at 1 month, they will receive combination treatment with both midodrine and
atomoxetin. The primary outcome measure is amelioration of questionnaire score evaluating
OH-associated symptoms at 3 months. Secondary end-points were improvement in orthostatic
blood pressure (BP) drop at 1 and 3 months.